Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

595
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
595
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

600
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
600
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

331
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
331
Sex-linked Disorders01:43

Sex-linked Disorders

106.7K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
106.7K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.3K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.3K
Amyloid Fibrils03:03

Amyloid Fibrils

11.4K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.

Journal of autoimmunity·2026
Same author

Sudden cardiac death and major arrhythmic events in patients with Fabry disease: Risk stratification in the French Heart Fabry cohort multicenter study.

Heart rhythm·2026
Same author

[Proposals from the French National Society of Internal Medicine on care pathways for patients with medical emergencies].

La Revue de medecine interne·2026
Same author

Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results.

Journal of inherited metabolic disease·2026
Same author

Treatment-related benefit and satisfaction in patients with Fabry disease in France: insight into patients' expectations and preferences from the prospective, non-interventional SATIS-Fab study.

Orphanet journal of rare diseases·2026
Same author

Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulation.

Journal of internal medicine·2026
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Related Experiment Video

Updated: Dec 5, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.4K

[Fabry disease].

Benjamin Subran1, Clémence Montagner1, Jonathan London1

  • 1Service de médecine interne, groupe hospitalier Diaconesses Croix-Saint Simon, Paris, France.

La Revue Du Praticien
|October 15, 2020
PubMed
Summary
This summary is machine-generated.

Fabry disease is an X-linked genetic disorder caused by a deficiency in alpha-galactosidase A. Early diagnosis and available treatments like enzyme replacement therapy can manage this rare condition.

Keywords:
Fabry disease

More Related Videos

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.6K
Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms
08:32

Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms

Published on: March 22, 2024

1.5K

Related Experiment Videos

Last Updated: Dec 5, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.4K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.6K
Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms
08:32

Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms

Published on: March 22, 2024

1.5K

Area of Science:

  • Genetics
  • Biochemistry
  • Rare Diseases

Background:

  • Fabry disease is a rare X-linked genetic disorder.
  • It results from a deficiency of the enzyme alpha-galactosidase A.
  • This deficiency causes harmful substrate accumulation, leading to tissue dysfunction.

Purpose of the Study:

  • To provide an overview of Fabry disease.
  • To highlight key diagnostic indicators and methods.
  • To mention available therapeutic options.

Main Methods:

  • Diagnosis relies on enzymatic assays for males.
  • Genetic testing is essential for accurate diagnosis in females.
  • Clinical presentation includes acroparesthesia, angiokeratoma, nephropathy, and cardiomyopathy.

Main Results:

  • Enzyme-substrate accumulation is the primary pathological mechanism.
  • Specific symptoms like acroparesthesia and angiokeratoma are indicative of the disease.
  • Effective diagnostic tools are available for both genders.

Conclusions:

  • Fabry disease requires timely diagnosis for effective management.
  • Enzyme replacement therapy has been available since 2001.
  • Pharmacologic chaperone therapy offers another treatment option since 2016.